On Friday, the FDA granted supplemental BLA for ILUMYA in adult psoriatic arthritis, adding a new indication to Sun Pharma’s portfolio. The company’s NSE‑listed shares rose 2.12% at 09:20 a.m., extending a four‑day uptrend.
The stock has surged 4.49% year‑to‑date and 5.57% over the past 12 months, outpacing the broader biopharma index, which climbed 1.8% YTD. Analysts had previously priced the company at a 2% gain on the day, so the 2.12% rally beats expectations.
ILUMYA, a sub‑cutaneous IL‑23 inhibitor, received approval on the basis of Phase‑3 INSPIRE‑1 and 2 trials that demonstrated a 48% reduction in joint damage at week 24. Rick Ascroft, North America CEO, said the approval "expands the drug’s indication beyond skin disease into joint pathology." The safety profile remains unchanged, with upper respiratory tract infections and COVID‑19 being the most common adverse events.
Sun Pharma has not issued new guidance but expects continued incremental revenue from ILUMYA’s expanded indication. The company will report Q4 results on 30‑Nov‑26, and investors will be watching for any impact on the drug’s pricing strategy and global launch plan.